-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师的观点总结如下： ATCO公布第一季度调整后收益为1.65亿加元（每股1.47加元），较上年同期增长500万加元，调整项目包括700万加元的未实现商品收益和1900万加元的受监管时间调整。ATCO Structures获得了超过3亿加元的合同，涵盖加拿大西部和澳大利亚的矿业项目、员工住房和数据中心。公司投入资本支出3.53亿加元，其中94%用于受监管的公用事业项目，并完成了CETO输电线路的建设，预计将于2026年6月投入使用。价值29亿加元的Yellowhead管道项目正在推进监管审批，AUC听证会定于2026年5月举行。董事会维持季度股息为每股0.5196加元（年化2.08加元）。我们相信，ATCO多元化的项目组合和战略投资使公司处于良好的发展地位，并辅以强劲的融资策略，计划在2026年至2030年期间发行8亿加元的资本证券。
Related Articles
Australia
Aptiv Stock Sell-off Post Q1 Results was Unwarranted, UBS Says
Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%
$APTV$F
Research
Wells Fargo Downgrades Criteo to Equalweigt From Overweight, $18 Price Target
Price: $15.79, Change: $-4.34, Percent Change: -21.55%
$CRTO
Australia
Ocular Therapeutix Advances FDA Talks on Single-Trial Filing for Eye Drug, RBC Says
Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%
$OCUL